Successful management of refractory neonatal seizures with midazolam

Deepa Sirsi, Srishti Nangia, Jacqueline LaMothe*, Barry E. Kosofsky, Gail E. Solomon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Seizures are indicative of underlying neurologic dysfunction in neonates. Repeated seizures may be deleterious to the brain even without disturbances of ventilation or perfusion. First-line antiepileptic drugs such as phenobarbital and phenytoin are not very effective in controlling seizures in neonates. Rapid control of status epilepticus with midazolam has been demonstrated in 2 previous studies with complete clinical and electrographic response in neonates who did not respond to phenobarbital and phenytoin. We report our experience with 3 neonates with status epilepticus. Seizures in all 3 neonates did not respond to phenobarbital and phenytoin but responded to midazolam infusion. Midazolam may be considered a safe and effective antiepileptic drug in refractory neonatal seizures of diverse etiologies.

Original languageEnglish (US)
Pages (from-to)706-709
Number of pages4
JournalJournal of child neurology
Issue number6
StatePublished - Jun 1 2008


  • Midazolam
  • Neonatal seizures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Successful management of refractory neonatal seizures with midazolam'. Together they form a unique fingerprint.

Cite this